Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma

Up to 30% of patients with classical Hodgkin lymphoma (cHL) are not responsive to frontline therapy or relapse after primary treatment. In these cases, autologous hematopoietic stem cell transplantation (AHSCT) is the standard of care. The combination of brentuximab vedotin and bendamustine (BV + B)...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinczés, László Imre, Szabó, Roxána, Illés, Árpád, Földeák, Dóra, Piukovics, Klára, Szomor, Árpád, Gopcsa, László, Miltényi, Zsófia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481161/
https://www.ncbi.nlm.nih.gov/pubmed/32748163
http://dx.doi.org/10.1007/s00277-020-04204-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481161/
https://www.ncbi.nlm.nih.gov/pubmed/32748163
http://dx.doi.org/10.1007/s00277-020-04204-1

Ejemplares similares